Navigation Links
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Date:9/4/2009

g maturity."

The tafoxiparin Phase II trial was designed to measure the effect on labor time after preventive treatment using the candidate drug. 263 women at 18 clinics in Sweden were included in a randomized, double-blind and placebo-controlled study, conducted over a two year period. The treatment, which was administered during the last phase of pregnancy, was shown to be safe and well tolerated. In the groups as a whole the labor time was shorter in the treated group, but did not reach statistical significance.

However, further analyses of results suggest that treatment with tafoxiparin provides beneficial effects, including: a statistically significant (p=0.04) reduction in the number of women with labor times in excess of twelve hours; fewer complications as a cause of protracted labor; and fewer caesarean sections as a result of protracted labor.

Dilafor's CEO, Anders Asell, commented, "By concluding this proof-of-concept study we have shown that tafoxiparin has the potential to solve an important unmet medical need. We will now start actively seeking a collaboration partner with whom we can carry out a Phase III program. Parallel to this we will continue to develop tafoxiparin within Dilafor."

About Dilafor AB

Established in 2003, Dilafor AB is a Swedish R&D company focused on developing pharmaceutical products from heparin derivatives with low anticoagulant activity. The company has a balanced product portfolio representing highly promising ideas and innovations. Each of the projects addresses important and unmet medical needs.

The project, tafoxiparin (DF01) for protracted labor, successfully concluded a clinicial Phase II study in July 2009. DF02, a drug candidate for the treatment of severe malaria, is presently in Phase I clinical development.

Dilafor is managed by senior staff with high academic credentials and extensive industrial
'/>"/>

SOURCE Karolinska Development AB PUBL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BioPharma Inc. (NASDAQ: ARRY ) today announced ... Pharma AG to acquire worldwide rights to encorafenib (LGX818), ... agreement is conditional on the closing of transactions announced by ... are expected to close in the first half of ...
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... The laboratory information management systems market is ... of technological advancements due to factors such as rising ... integrate healthcare systems, and increasing government support for adoption ... Key players in the market focus on technological advancements ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... SOUTH SAN FRANCISCO, Calif. , April 29 ... creating new therapeutics discovered using cellular reprogramming and directed ... been awarded a three-year $1.5 million "Basic ... (CIRM). The grant will be used to fund the ...
... April 29 HEALTHeCAREERS Network , North America ,s ... , , ... , , , ... Angiography and Interventions (SCAI) recently joined the Network, launching the SCAI ...
... CHICAGO , April 29  Scotland ... attracted many of the world,s leading pharma and biotech ... May 3-6 in Chicago .  Heading ... Scottish research and the nation,s unique integrated industry approach ...
Cached Biology Technology:iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming 2iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming 3Healthcare Web site Expands Reach to Cardiology Professionals 2Healthcare Web site Expands Reach to Cardiology Professionals 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 2Scotland Announces New Life Science Leadership and Investments at BIO 2010 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 4
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... researchers have developed a methodology for governments and corporations ... a paper in Environmental Science & Technology . ... evaluate the importance of scarce metals using a methodology ... to supply restriction. "In the past few ...
... 2012 DNA sequencing to detect genetic mutations ... for cancer. Current methods of testing DNA samples, ... can be difficult or impossible to interpret. Scientists ... developed a free software program, Pyromaker, that can more ...
... ALBANY, Calif.Sudden oak death, Port-Orford-cedar root disease and ... species (pronounced fy-TOF-ther-uhs) are threatening forest ecosystems worldwide. ... spend part of their life cycle in soil or ... them. A new web site, developed jointly by ...
Cached Biology News:New methodology assesses risk of scarce metals 2New virtual tool may provide more accurate diagnosis of genetic mutations 2New website shares information about deadly tree pathogens 2
... of Japan, also named Sendai virus) Envelope ... of molecules by means of membrane fusion. ... Protein, Oligo, cDNA, Antibodies, Vector, and Biomolecule ... EX has a high fusing capability in ...
... S. pombe Whole Genome ChIP-on-chip Microarray ... of yeast (S. pombe) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... designed for easy transformation of the budding ... successful transformation simply by mixing a plasmid ... yeast cells. No complicated steps, such as ... kit is particularly well suited for high-throughput ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Biology Products: